

Michael SchÄ¶ll

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1341121/publications.pdf>

Version: 2024-02-01

134
papers

10,404
citations

53939

47
h-index

42259

96
g-index

147
all docs

147
docs citations

147
times ranked

10474
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma p-tau231, p-tau181, ^{18F}PET Biomarkers, and Cognitive Change in Older Adults. <i>Annals of Neurology</i> , 2022, 91, 548-560.	2.8	42
2	Association of APOE ε4 and Plasma p-tau181 with Preclinical Alzheimer's Disease and Longitudinal Change in Hippocampus Function. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1309-1320.	1.2	11
3	Plasma and CSF NfL are differentially associated with biomarker evidence of neurodegeneration in a community-based sample of 70-year-olds. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12295.	1.2	11
4	CSF biomarkers and plasma p-tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design. <i>Alzheimer's and Dementia</i> , 2022, 18, 2614-2626.	0.4	22
5	Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic Symptoms. <i>JAMA Network Open</i> , 2022, 5, e2213253.	2.8	35
6	Association of Plasma Biomarker Levels With Their CSF Concentration and the Number and Severity of Concussions in Professional Athletes. <i>Neurology</i> , 2022, 99, .	1.5	10
7	Imaging tau pathology in Alzheimer's disease with positron emission tomography: lessons learned from imaging-neuropathology validation studies. <i>Molecular Neurodegeneration</i> , 2022, 17, .	4.4	5
8	Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. <i>Brain</i> , 2021, 144, 325-339.	3.7	124
9	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. <i>Molecular Psychiatry</i> , 2021, 26, 429-442.	4.1	186
10	Reduced [¹⁸ F]flortaucipir retention in white matter hyperintensities compared to normal-appearing white matter. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2283-2294.	3.3	9
11	Head-to-head comparison of amplified plasmonic exosome Aβ ₄₂ platform and single-molecule array immunoassay in a memory clinic cohort. <i>European Journal of Neurology</i> , 2021, 28, 1479-1489.	1.7	11
12	Pre- and postoperative ⁶⁸ Ga-DOTATOC positron emission tomography for hormone-secreting pituitary neuroendocrine tumours. <i>Clinical Endocrinology</i> , 2021, 94, 956-967.	1.2	7
13	Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. <i>Acta Neuropathologica</i> , 2021, 141, 709-724.	3.9	285
14	Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β ² and tau deposition in older individuals without dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2212-2224.	3.3	29
15	Discriminatory ability of next-generation tau PET tracers for Alzheimer's disease. <i>Brain</i> , 2021, 144, 2284-2290.	3.7	29
16	Bispecific Tau Antibodies with Additional Binding to C1q or Alpha-Synuclein. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 813-829.	1.2	2
17	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 396.	4.5	146
18	Tau Seeding Mouse Models with Patient Brain-Derived Aggregates. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6132.	1.8	14

#	ARTICLE	IF	CITATIONS
19	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021, 12, 3400.	5.8	219
20	Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. <i>Neurology</i> , 2021, 97, .	1.5	50
21	Microglial activation and tau propagate jointly across Braak stages. <i>Nature Medicine</i> , 2021, 27, 1592-1599.	15.2	235
22	Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1231-1241.	0.9	51
23	Deep learning from MRI-derived labels enables automatic brain tissue classification on human brain CT. <i>NeuroImage</i> , 2021, 244, 118606.	2.1	13
24	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1145-1156.	0.4	174
25	Current advances in digital cognitive assessment for preclinical Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12217.	1.2	63
26	Comparison of Two-Dimensional- and Three-Dimensional-Based U-Net Architectures for Brain Tissue Classification in One-Dimensional Brain CT. <i>Frontiers in Computational Neuroscience</i> , 2021, 15, 785244.	1.2	9
27	Tau pathology progression across PET-based stages of regional amyloid deposition. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
28	Impact of reduced injected dose on the quantification of [¹⁸ F]RO948 and [¹⁸ F]Flortaucipir PET for <i>in vivo</i> tau pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
29	When is a biomarker an AD biomarker? Face versus construct validity and practical implications for differential application. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
30	Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of patients with mixed pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
31	Associations of fully automated Elecsys CSF and novel plasma biomarkers with Alzheimer's disease neuropathology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
32	Current status and quantitative results of the AMYPAD prognostic and natural history study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
33	Association of cerebrospinal fluid and plasma biomarkers with longitudinal tau accumulation. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
34	Plasma and cerebrospinal fluid neurofilament light protein concentrations are differentially associated with biomarker evidence of neurodegeneration in a community-based population of 70-year-olds. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
35	Association of deep learning-derived brain computed tomography measures with cognition and blood-based biomarkers of neurodegenerative diseases. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
36	Propagation of Tau Pathology: Integrating Insights From Postmortem and <i>In Vivo</i> Studies. <i>Biological Psychiatry</i> , 2020, 87, 808-818.	0.7	50

#	ARTICLE	IF	CITATIONS
37	Head-to-head comparison of tau positron emission tomography tracers [¹⁸ F]flortaucipir and [¹⁸ F]RO948. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 342-354.	3.3	61
38	Does early cognitive decline require the presence of both tau and amyloid- β ?. <i>Brain</i> , 2020, 143, 10-13.	3.7	9
39	Lower ⁶⁸ Ga-DOTATOC uptake in nonfunctioning pituitary neuroendocrine tumours compared to normal pituitary gland – A proof-of-concept study. <i>Clinical Endocrinology</i> , 2020, 92, 222-231.	1.2	11
40	Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. <i>Brain</i> , 2020, 143, 3793-3804.	3.7	60
41	CT-based brain segmentation and volumetry using deep learning methods. <i>Alzheimer's and Dementia</i> , 2020, 16, e045824.	0.4	0
42	Relevance of biomarkers across different neurodegenerative diseases. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 56.	3.0	42
43	Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course – a joint PhD student course at University College London and University of Gothenburg. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 20.	3.0	32
44	University College London/University of Gothenburg PhD course – Biomarkers in neurodegenerative diseases – 2019 – course organisation. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 18.	3.0	0
45	Imaging biomarkers in neurodegeneration: current and future practices. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 49.	3.0	96
46	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 265-284.	4.9	121
47	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <i>Lancet Neurology</i> , The, 2020, 19, 422-433.	4.9	668
48	PET Biomarkers for Tau Pathology. , 2020, , 227-234.		0
49	Regional times to equilibria and their impact on semi-quantification of [¹⁸ F]AV-1451 uptake. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 2223-2232.	2.4	5
50	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. <i>Journal of Neurology</i> , 2019, 266, 2535-2545.	1.8	11
51	Comparative analysis of obesity-related cardiometabolic and renal biomarkers in human plasma and serum. <i>Scientific Reports</i> , 2019, 9, 15385.	1.6	19
52	Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. <i>Acta Neuropathologica Communications</i> , 2019, 7, 5.	2.4	125
53	Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 679-689.	1.2	48
54	Predicting diagnosis and cognition with ¹⁸ F-AV-1451 tau PET and structural MRI in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 570-580.	0.4	84

#	ARTICLE	IF	CITATIONS
55	Synaptic vesicle protein 2A as a potential biomarker in synaptopathies. <i>Molecular and Cellular Neurosciences</i> , 2019, 97, 34-42.	1.0	55
56	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. <i>Science Advances</i> , 2019, 5, eaau7220.	4.7	59
57	A walk through tau therapeutic strategies. <i>Acta Neuropathologica Communications</i> , 2019, 7, 22.	2.4	211
58	O1a07a02: LONGITUDINAL ASSOCIATIONS BETWEEN PLASMA NFL AND VOXEL-BASED MORPHOMETRY IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, .	0.4	0
59	F4a05a01: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN PET IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P1224.	0.4	0
60	O2a05a01: CEREBROSPINAL FLUID SYNAPTIC VESICLE GLYCOPROTEIN 2A IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P545.	0.4	2
61	ICaPa070: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN PET IN THE ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P64.	0.4	1
62	ICaPa071: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN ATROPHY IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P65.	0.4	0
63	ICaPa072: LONGITUDINAL ASSOCIATIONS BETWEEN PLASMA NFL AND VOXEL-BASED MORPHOMETRY IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P66.	0.4	0
64	Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease. <i>Human Brain Mapping</i> , 2019, 40, 638-651.	1.9	27
65	Biomarkers for tau pathology. <i>Molecular and Cellular Neurosciences</i> , 2019, 97, 18-33.	1.0	163
66	O5a01a01: HEAD-TO-HEAD IN VIVO COMPARISON OF TAU POSITRON EMISSION TOMOGRAPHY LIGANDS ¹⁸ F-FLORTAUCIPIR AND ¹⁸ F-RO948. <i>Alzheimer's and Dementia</i> , 2019, 15, .	0.4	1
67	Comparing ¹⁸ F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. <i>Neurology</i> , 2018, 90, e388-e395.	1.5	83
68	¹⁸ F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies. <i>Scientific Reports</i> , 2018, 8, 4717.	1.6	59
69	ICaPa0218: ¹⁸ F-FLORTAUCIPIR (AV-1451) RETENTION IN PARKINSON'S DISEASE AND DEMENTIA WITH LEWY BODIES. <i>Alzheimer's and Dementia</i> , 2018, 14, P178.	0.4	0
70	P3a0243: THE ASSOCIATION OF LONGITUDINAL PLASMA NFL WITH POSTMORTEM NEUROPATHOLOGY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1165.	0.4	0
71	Discriminative Accuracy of [¹⁸ F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1151.	3.8	298
72	Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 1305-1311.	1.3	16

#	ARTICLE	IF	CITATIONS
73	No association of salivary total tau concentration with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 70, 125-127.	1.5	51
74	Effects of APOE ϵ 4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 71, 81-90.	1.5	15
75	Molecular properties underlying regional vulnerability to Alzheimer's disease pathology. <i>Brain</i> , 2018, 141, 2755-2771.	3.7	89
76	Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 45.	3.0	11
77	Update on biomarkers for amyloid pathology in Alzheimer's disease. <i>Biomarkers in Medicine</i> , 2018, 12, 799-812.	0.6	59
78	Detection of Alzheimer's Disease. <i>Yale Journal of Biology and Medicine</i> , 2018, 91, 291-300.	0.2	21
79	The continuum of spreading depolarizations in acute cortical lesion development: Examining Leão's legacy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 1571-1594.	2.4	297
80	Recording, analysis, and interpretation of spreading depolarizations in neurointensive care: Review and recommendations of the COSBID research group. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 1595-1625.	2.4	255
81	Amyloid and tau PET demonstrate region-specific associations in normal older people. <i>NeuroImage</i> , 2017, 150, 191-199.	2.1	67
82	Increased basal ganglia binding of ^{18}F -AV-1451 in patients with progressive supranuclear palsy. <i>Movement Disorders</i> , 2017, 32, 108-114.	2.2	111
83	Linking Amyloid- β and Tau Deposition in Alzheimer Disease. <i>JAMA Neurology</i> , 2017, 74, 766.	4.5	10
84	Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy. <i>Acta Neuropathologica</i> , 2017, 133, 149-151.	3.9	61
85	Earliest accumulation of β -amyloid occurs within the default-mode network and concurrently affects brain connectivity. <i>Nature Communications</i> , 2017, 8, 1214.	5.8	596
86	In vivo retention of ^{18}F -AV-1451 in corticobasal syndrome. <i>Neurology</i> , 2017, 89, 845-853.	1.5	103
87	^{18}F -AV-1451 and CSF τ and $\text{P}\tau$ as biomarkers in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2017, 9, 1212-1223.	3.3	156
88	[ICP-199]: [^{18}F -AV-1451 PET IN CLINICALLY DIAGNOSED CORTICOBASAL DEGENERATION. <i>Alzheimer's and Dementia</i> , 2017, 13, P146.	0.4	0
89	[O1-06-06]: SPATIAL CORRESPONDENCE OF ALZHEIMER'S DISEASE-RELATED TAU PATHOLOGY AND GREY MATTER ATROPHY DISTRIBUTION WITH INTRINSIC FUNCTIONAL BRAIN NETWORKS. <i>Alzheimer's and Dementia</i> , 2017, 13, P203.	0.4	0
90	[P4-407]: REGIONAL DIFFERENCES IN THE TRANSIENT EQUILIBRIUM OF [^{18}F -AV-1451 AND THEIR IMPACT ON TISSUE UPTAKE RATIOS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1486.	0.4	0

#	ARTICLE	IF	CITATIONS
91	[P4â€“502]: THE EARLIEST STAGES OF AMYLOID ACCUMULATION ARE ASSOCIATED WITH INCREASED FUNCTIONAL CONNECTIVITY IN NONâ€“DEMENTED ELDERLY SUBJECTS. Alzheimer's and Dementia, 2017, 13, P1531.	0.4	0
92	[P4â€“525]: DATAâ€“DRIVEN TAUâ€“PET COVARIANCE NETWORKS ENHANCE PREDICTION OF RETROSPECTIVE COGNITIVE CHANGE IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1548.	0.4	1
93	Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimerâ€™s disease. Brain, 2017, 140, 2286-2294.	3.7	149
94	Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks. Frontiers in Neuroscience, 2017, 11, 167.	1.4	87
95	[ICâ€“Pâ€“195]: SPATIAL CORRESPONDENCE OF ALZHEIMER'S DISEASEâ€“RELATED TAU PATHOLOGY AND GREY MATTER ATROPHY DISTRIBUTION WITH INTRINSIC FUNCTIONAL BRAIN NETWORKS. Alzheimer's and Dementia, 2017, 13, P143.	0.4	0
96	¹⁸F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in <i>MAPT</i> mutation carriers. Brain, 2016, 139, 2372-2379.	3.7	149
97	P4â€“339: Earlyâ€“and Lateâ€“Onset Alzheimerâ€™s Disease are Associated with Distinct Regional TAU Pathology as Examined with [18]Fâ€“AVâ€“1451 TAU Positron Emission Tomography. Alzheimer's and Dementia, 2016, 12, P1164.	0.4	0
98	IC-P-193: Examining Amyloid and TAU Inter-Regional PET Association Patterns in Cognitively Normal Older Adults. , 2016, 12, P139-P140.		0
99	P1â€“318: TAUâ€“PET Patterns Overlap and Exceed Hypometabolism in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P545.	0.4	2
100	O3â€“08â€“04: Tau Covariance Patterns in Alzheimer's Disease Patients Resemble Intrinsic Connectivity Networks in Young Adults. Alzheimer's and Dementia, 2016, 12, P305.	0.4	0
101	O4-09-01: An Nrem Sleep Signature of Human in Vivo TAU Burden. , 2016, 12, P353-P353.		0
102	PET Imaging of Tau Deposition in the Aging Human Brain. Neuron, 2016, 89, 971-982.	3.8	899
103	Accelerating rates of cognitive decline and imaging markers associated with β -amyloid pathology. Neurology, 2016, 86, 1887-1896.	1.5	42
104	ICâ€“Pâ€“192: TAU Covariance Patterns in ad Patients Resemble Intrinsic Connectivity Networks in Young Adults. Alzheimer's and Dementia, 2016, 12, P138.	0.4	0
105	Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimerâ€™s disease. Brain, 2016, 139, 922-936.	3.7	235
106	Comparison of Early-Phase ¹¹C-Deuterium-l-Deprenyl and ¹¹C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease. Journal of Nuclear Medicine, 2016, 57, 1071-1077.	2.8	63
107	Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimerâ€™s disease. Brain, 2016, 139, 1551-1567.	3.7	833
108	IC-P-126: Divergent pattern of changes in astrocytosis and fibrillar amyloid plaques as measured by PET in autosomal-dominant and sporadic Alzheimer's disease. , 2015, 11, P86-P86.		0

#	ARTICLE	IF	CITATIONS
109	IC-P-161: Tau PET with [18 F]AV1451 in non-alzheimer's disease neurodegenerative syndromes. , 2015, 11, P107-P109.		4
110	IC-02-02: Distinct [18 F]AV1451 retention patterns in clinical variants of Alzheimer's disease. , 2015, 11, P5-P6.		1
111	IC-01-05: In vivo braak staging using 18F-AV1451 Tau PET imaging. , 2015, 11, P4-P4.		5
112	Early astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography. Scientific Reports, 2015, 5, 16404.	1.6	110
113	IC-P-157: Associations of [18 F]AV1451 Tau PET with age, ApoE genotype, and cognition in Alzheimer's disease. , 2015, 11, P105-P106.		0
114	Multimodality Imaging Approaches in Alzheimer's disease. Part II: 1H MR spectroscopy, FDG PET and Amyloid PET. Dementia E Neuropsychologia, 2015, 9, 330-342.	0.3	4
115	Multimodality Imaging Approach in Alzheimer disease. Part I: Structural MRI, Functional MRI, Diffusion Tensor Imaging and Magnetization Transfer Imaging. Dementia E Neuropsychologia, 2015, 9, 318-329.	0.3	19
116	Prediction of AD dementia by biomarkers following the NIA's and IWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimer's and Dementia, 2015, 11, 1191-1201.	0.4	71
117	IC-P-168: Examining relations of age and beta-amyloid with tau deposition measured using 18F-AV-1451 in cognitively normal older adults. , 2015, 11, P111-P112.		0
118	O1-07-02: Alzheimer's disease core biomarkers and prediction of dementia in MCI: The effect of age at onset. , 2015, 11, P140-P142.		0
119	F2-03-01: Tau and amyloid neuroimaging of ad phenotypes. , 2015, 11, P167-P167.		0
120	O5-01-04: Cognitive decline in healthy elderly is related to temporal lobe tau but not to cortical β -amyloid: An 18F-AV1451 and 11C-PiB PET study. , 2015, 11, P313-P314.		0
121	Mild cognitive impairment with suspected nonamyloid pathology (SNAP). Neurology, 2015, 84, 508-515.	1.5	122
122	Amyloid biomarkers in Alzheimer's disease. Trends in Pharmacological Sciences, 2015, 36, 297-309.	4.0	404
123	Astrocytosis measured by 11C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2120-2126.	3.3	53
124	Fluorodeoxyglucose PET in Neurology and Psychiatry. PET Clinics, 2014, 9, 371-390.	1.5	58
125	O2-13-03: MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NON AD PATHOLOGY (SNAP): PREDICTION OF PROGRESSION TO DEMENTIA. , 2014, 10, P194-P195.		0
126	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology, 2013, 80, 1048-1056.	1.5	161

#	ARTICLE	IF	CITATIONS
127	Combination of 18F-FDG PET and Cerebrospinal Fluid Biomarkers as a Better Predictor of the Progression to Alzheimer's Disease in Mild Cognitive Impairment Patients. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 929-939.	1.2	48
128	Cortical Spreading Depression Dynamics Can Be Studied Using Intrinsic Optical Signal Imaging in Gyrencephalic Animal Cortex. , 2013, 118, 93-97.		13
129	Evidence for Astrocytosis in Prodromal Alzheimer Disease Provided by ¹¹ C-Deuterium-L-Deprenyl: A Multitracer PET Paradigm Combining ¹¹ C-Pittsburgh Compound B and ¹⁸ F-FDG. <i>Journal of Nuclear Medicine</i> , 2012, 53, 37-46.	2.8	354
130	Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic <i>APP</i> mutation carriers. <i>Neurology</i> , 2012, 79, 229-236.	1.5	138
131	Glucose metabolism and PiB binding in carriers of a His163Tyr presenilin 1 mutation. <i>Neurobiology of Aging</i> , 2011, 32, 1388-1399.	1.5	48
132	Biomarkers for Microglial Activation in Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-5.	1.1	23
133	Time Course of Glucose Metabolism in Relation to Cognitive Performance and Postmortem Neuropathology in Met146Val PSEN1 Mutation Carriers. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 495-506.	1.2	30
134	Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. <i>Brain</i> , 2011, 134, 301-317.	3.7	126